This project received funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement No 822455.

Reducing the cost, time, and ethical burden of preclinical research in the pharmaceutical industry

Modern drug discovery is an inefficient, expensive and risky process. The average cost of a successful drug introduction now exceeds $3bn, with a time to market in excess of 10 years. The consumption of patent life during R&D has a profound financial impact with the decreasing economic life of an approved drug leading to increased market costs. **The key bottleneck and attrition point in drug discovery is the hit to lead transition from early hits identified by multiple approaches (including genomics, proteomics, high throughput screening, AI) and in vivo proof of target**

Genome Biologics overcomes the inefficiencies of current drug repositioning and development strategies



Our AI-driven Drug-Disease matching platform works in concert with the patented multi-disease modeling transgenesis technology facilitating more efficient and ethical drug development and positioning. The toolkit reduces the time to prepare animal models, and the cost of drug discovery and pre-clinical trials, by an order of magnitude. The impact of this is cheaper, more rapidly developed drugs, with a greater target to market success rate.

The undergoing project is executed through the work packages below

Work Package 1: Technology Advancement and Industrial Validation	**Work Package 2:** Commercial Trials – Small Animal Models, Joint Development	**Work Package 3:** Commercial Trials – Large Animal Models
Work Package 4: Marketing, Exploitation, Commercialization	**Work Package 5:** Project Management	**Work Package 6:** Ethics requirements